Investor082
11 minutes ago
Gary,
The TAM for Alzheimer’s is massive. GBM is a small market. Plus manufacturing is complex, hard to scale and expensive for NWBO product as compared to AVXL.
So you’re comparing apples to oranges. If AVXL drug gets approved in the EU, they will indeed deserve a big